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Abstract
Background: The host response to intruders in the central nervous system (CNS) may be beneficial but could also
be harmful and responsible for neurologic symptoms and sequelae in CNS infections. This immune response
induces the activation of the kynurenine pathway (KP) with the production of neuroactive metabolites. Herein, we
explored cytokine and KP responses in cerebrospinal fluid (CSF) and serum in patients with encephalitis, aseptic,
and bacterial meningitis.
Methods: Cytokines were measured in CSF and serum by multiplex assay in adult patients with encephalitis of
infectious, autoimmune or unknown etiology (n = 10), aseptic meningitis (ASM, n = 25), acute bacterial meningitis
(ABM, n = 6), and disease control patients with similar symptoms but without pleocytosis in CSF (n = 42). Liquid
chromatography-tandem mass spectrometry (LC-MS/ MS) was used to measure KP metabolites in CSF and serum.
Results: A characteristic pattern of increasing cytokine levels and KP metabolites was found in CSF from encephalitis
to ASM, with the highest levels in ABM. In ASM and ABM, most inflammatory mediators, including IL-6, IL-8, and IFN-
inducible protein-10 (IP-10), showed markedly elevated levels in CSF compared with serum, indicating
production within the CNS. In contrast to most mediators, the highest level of IP-10 was found in the ASM
group, suggesting a potential role for IP-10 in aseptic/viral meningitis. Neopterin and IP-10 were associated
with marked changes in KP metabolites in CSF with increasing kynurenine/tryptophan ratio reflecting
indoleamine 2,3-dioxygenase activity. Neopterin, a marker of IFN-γ activity, was associated with an unfavorable
balance between neuroprotective and neurotoxic tryptophan metabolites.
Conclusion: We show that parenchymal and meningeal inflammations in CNS share a characteristic cytokine
profile with a general immune response in the CSF with limited influence from the systemic circulation. IFN-γ
activity, assessed by neopterin and IP-10 levels, may play a role in the activation of the KP pathway in these
patients, potentially mediating neurotoxic effects.
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Background
The host inflammatory response to intruders to the
central nerve system (CNS) plays an important role
for neuronal injury in encephalitis and meningitis.
The cytokine profiles of aseptic meningitis (ASM) and
acute bacterial meningitis (ABM) have been investi-
gated in several studies, in general showing increased
levels of inflammatory mediators [1–8]. However, for
encephalitis, inflammatory responses have mainly been
evaluated for patients with herpes simplex virus
(HSV) infection [9–13]. Thus, comparison of cytokine
levels in encephalitis, ASM and ABM and control pa-
tients are scarce. Moreover, most studies have focused
on a limited number of inflammatory markers, and
few studies have examined parallel samples of serum
and cerebrospinal fluid (CSF) from the same patients.
It is known that the inflammation activates the
kynurenine pathway (KP) resulting in the depletion of
tryptophan (TRP) and formation of metabolites with
potential neurotoxic (e.g., quinolinic acid [QA],
3-hydroxykynurenine [3-HK]) and neuroprotective
(e.g., kynurenic acid [KYNA]) effects (Fig. 1) [14, 15].
The activation of the KP seems to also have immune
modulating effects, resulting in inhibition of TH1
cells, activation of regulatory T cells (Tregs) and inhib-
ition of natural killer (NK) cells [16–19]. In the CNS,
the rate-limiting enzyme for TRP catabolism is
indoleamine 2,3-dioxygenase (IDO) which is upregu-
lated by inflammatory cytokines, mainly by interferon
gamma (IFN-γ) [20], linking T cell activation to the
regulation of the KP.
Altered cytokine levels and associated imbalance of
neurotoxic and neuroprotective metabolites in the KP
have been suggested to contribute to the pathogenesis of
several chronic conditions in the CNS, such as schizo-
phrenia [21, 22], bipolar disorders [23, 24], Parkinson’s
disease [25], Alzheimer’s [26] and Huntington’s disease
[27], and AIDS-related dementia [28, 29], as well as in
traumatic brain injury [30]. However, there is limited
data on the role of KP in acute infections like encephal-
itis and meningitis, although increased levels of KYNA
have been shown in patients with HSV encephalitis,
Lyme borreliosis, tick-borne encephalitis, and bacterial
meningitis [4, 31–33]. Moreover, altered tryptophan me-
tabolism has been linked to disease severity in tubercu-
lous meningitis [34].
The aim of the present study was to elucidate the in-
flammatory network and KP metabolites in ASM and
ABM, characterized by meningeal inflammation, and in
encephalitis, characterized by brain parenchymal inflam-
mation. Parallel samples of serum and CSF were exam-
ined in patient groups and control patients, i.e., patients
with similar symptoms but without CSF pleocytosis or
other signs of CNS infection.
Fig. 1 Schematic presentation of the KP pathway. IDO is the main enzyme responsible for the TRP catabolism in CNS. KYN is further degraded
into the neuroprotective NMDAr antagonist KYNA by KAT, or by KMO and KYNU into the neurotoxic metabolites of 3-HK and QA. QA is an
agonist of the NMDA receptor. Abbreviations: AA, anthranilic acid; 3-HAA, 3-hydroxyanthranilic acid; HAO, 3-hydroxyanthranilic acid oxidase; 3-HK,
3-hydroxykynurenine; IDO, indoleamine-2,3-dioxygenase; KAT, kynurenine aminotransferase; KMO, kynurenine 3-monooxygenase; KYN, kynurenine;
KYNA, kynurenic acid; KYNU, kynureninase; QA, quinolinic acid; PIC, picolinic acid; TRP, tryptophan; XA, xanthurenic acid. Bold box indicates
neuroprotective metabolite, dashed boxes indicate neurotoxic metabolites in the KP pathway
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Methods
Study participants and study design
This cross-sectional study was performed at the Oslo Uni-
versity Hospital (OUS), Ullevaal, a regional hospital for 2.7
million people. Patients were eligible for inclusion if they
had (1) onset of symptoms of CNS infection within less
than 7 days and (2) clinical indication for a diagnostic
lumbar puncture (LP). Patients were included between
January 2014 and December 2015. CSF leukocyte counts
≥ 5 × 106 /L was found in 68 patients. Of these, 23 did not
fulfill the case definition of encephalitis of viral, auto-
immune or unknown cause, aseptic meningitis (ASM), or
bacterial meningitis (ABM) (Additional file 1: Table S1).
In four patients, the time from CSF sampling until centri-
fugation was > 10 h, rendering a total of 41 patients with
CNS infection (Additional file 2: Figure S1). The control
group consisted of age- and gender-matched patients with
similar symptoms, but without signs of CNS inflamma-
tion, i.e., no pleocytosis and no microbiological agent
detected in their CSF (n = 42). In the control group, pa-
tients with delirium, chronic or acute psychiatric disease,
Parkinson’s disease, Huntington’s disease, CNS malig-
nancy, dementia, epilepsy or seizures, cerebral vascular
disease, transient global amnesia, and septicemia were not
included. For detailed case definitions, see Additional file 1:
Table S1. Flowchart of the study population and the over-
view of analyses performed for the various groups are
shown in Additional file 2: Figure S1.
All patients, or their next of kin when the patient was
not able to consent, gave written informed consent to
participate in the study. The study was approved by The
Regional Committees for Medical and Health Research
Ethics (REC South East, reference number 2011/2578)
and the ethical council of the hospital.
Microbiological diagnostics
For all included patients, CSF leukocyte counts (CSF
WBC), CSF protein, and CSF glucose were measured.
Bacterial culture of CSF and analyses for identification
of causative agent were performed in all individuals by a
panel of specific PCR for common neurotropic virus and
bacteria.
Sampling of CSF and serum
CSF samples were collected in endotoxin-free polypro-
pylene tubes and stored at 4 °C until centrifugation at
2000×g for 10 min. Serum samples were collected in
endotoxin-free tubes without any additives, allowed to
clot at room temperature, and centrifuged at 3000×g for
10 min. Supernatants from CSF and serum were centri-
fuged within 10 h after collection and immediately fro-
zen in triplicates of approximately 700 μL each at − 80 °
C. All analyses were performed on previously unthawed
samples. For six patients, no serum was available.
Multiplex analyses of soluble markers in CSF and serum
A multiplex cytokine assay (Bio-Plex Pro Human Cytokine
27-plex Panel; Bio-Rad laboratories Inc. Hercules, CA)
was used to measure the concentrations of 27 different cy-
tokines: tumor necrosis factor (TNF), IFN-γ, interleukin
(IL)-1β, IL-1 receptor antagonist (IL-1Ra), IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12(p70), IL-13,
IL-15, IL-17A, monocyte chemoattractant protein
(MCP)-1/CCL2, IFN-inducible protein-10 (IP-10)/
CXCL10, eotaxin/CCL11, macrophage inflammatory
protein-1α and -1β (MIP-1α/CCL3, MIP-1β/CCL4), regu-
lated on activation, normal T cell expressed and secreted
(RANTES/CCL5), granulocyte-colony stimulating factor
(G-CSF), granulocyte-macrophage CSF (GM-CSF), basic
fibroblast growth factor (FGF), platelet-derived growth
factor (PDGF), and vascular endothelial growth factor
(VEGF). The assay was performed using the instructions
of the manufacturer. CSF samples were tested undiluted.
Only cytokines with less than 20% missing values were
included in further analyses. Undetectable levels were
assigned the lowest detectable level (LDL) measured in
the cohort for the respective marker. In the CSF samples,
IFN-γ, IL-5, PDGF, Basic FGF, and RANTES, and for
serum, IL-2, IL-5, IL-7, IL-15, G-CSF, GM-CSF, and FGF
were excluded from further analyses based on the criteria
stated above.
Mass spectrometry analyses of tryptophan metabolites in
CSF and serum
Tryptophan and kynurenine metabolites were measured
only in the patients with encephalitis, ASM with con-
firmed viral etiology (viral meningitis, VM), ABM, and
controls (Additional file 2: Figure S1). Concentrations of
TRP, kynurenine [KYN], anthranilic acid [AA], KYNA,
3-HK, 3-hydroxyanthranilic acid [3-HAA], xanthurenic
acid [XA], QA, picolinic acid [PIC], and neopterin were
analyzed in CSF and serum by liquid
chromatography-tandem mass spectrometry (LC-MS/
MS) by Bevital AS [35, 36]. For TRP, nine patients had
levels in CSF below the lower limit of detection (LOD).
As this may represent a finding rather than a limitation
by the analysis, these were set equal to the LOD
(0.4 μM) in the statistical analyses and in the calculation
of the KYN/TRP ratio (KYN (nmol)/TRP (μmol)) as an
index of IDO activity. XA was not detected in CSF for
46 of the 50 patients and was not included in the
analysis.
Statistical methods
Continuous data are presented as median (IQR, inter-
quartile range). Due to lack of normal distribution, ana-
lysis of variance (ANOVA) with the Kruskal-Wallis test
for multiple groups was used. If the Kruskal-Wallis test
revealed significant differences, the Mann-Whitney U
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test was used to compare pairs of groups. To limit type
II statistical errors, no correction for multiple compari-
sons was made in this explorative study. P values < 0.05
were considered statistically significant. Categorical vari-
ables are expressed as counts (percentages) and analyzed
by Pearson’s chi-square test. Correlations were analyzed
using Spearman’s rank correlation coefficient. All data
analyses were performed in SPSS version 24 (IBM Corp.
Armonk, NY, USA) and graphs generated by GraphPad
Prism 7 (GraphPad, San Diego, USA).
Results
Study participant characteristics
Ten patients had encephalitis of viral, autoimmune,
or unknown etiology according to the case definition
(Additional file 1: Table S1), 25 patients were diag-
nosed with ASM, six patients with ABM, and 42 were
control patients. Characteristics of the study group
are presented in Table 1. There were no significant
differences in gender or age between the patient
groups. In the CNS infection group, four patients re-
ported a history of depression, but only two of these
received antidepressant drugs. The etiology of enceph-
alitis was known for four patients (40%), three viral
(adenovirus, HSV1, varicella-zoster virus [VZV]) and
one N-methyl-D-aspartate receptor [NMDAr] enceph-
alitis. Of the 25 patients with ASM, eight were diag-
nosed with enterovirus in CSF, six patients suffered
from HSV2 meningitis, one patient seroconverted and
had positive IgM in CSF for Toscana virus, and for
one patient, intrathecal antibody production of IgG
against Borrelia burgdorferi was detected. For patients
with ABM, Streptococcus pneumoniae (n = 2),
Staphylococcus aureus (n = 2), Neisseria meningitidis
(n = 1), and Haemophilus influenzae (n = 1) were de-
tected in CSF by growth and/or PCR, and for all
Table 1 Patient characteristics and clinical presentation
Parameter Encephalitis (n = 10) ASM (n = 25) ABM (n = 6) Controls (n = 42) p valuea
Gender, males (%) 4 (40) 10 (40) 4 (67) 13 (31) 0.385
Age, years 43.5 (30, 72) 35 (28, 48) 52 (41, 68) 31 (22, 41) 0.054
Hospital stay, days 19 (11, 42)b 3 (1.5, 5.5)c 19 (14, 33)b, d 2.0 (1.0, 4.0) < 0.001
Comorbidity (%)
Immunodeficiencye 2 (30)b 1 (4)c 1 (17)b – 0.029
Psychiatric disorder 2 (20)b 2 (8) – – 0.046
Etiology known (%)f 4/10 (40) 16/25 (64) 6/6 (100) – < 0.001
Headache (%) 7/10 (70)b 24/25 (96)c 3/4 (75) 39/41 (95) 0.037
Neck stiffness (%)g 2/10 (20) 12/25 (48) 3/5 (60) 12/42 (29) 0.175
Objective fever (%)h 7/10 (70) 17/25 (68) 5/6 (83) 20/42 (48) 0.168
Focal neurology (%) 5/9 (56)b 2/19 (10)c 1/6 (17) 1/24 (4) 0.003
GCS ≤ 14 (%) 10/10 (100)b 2/25 (8)c 5/6 (83)b,d 6/42 (14) < 0.001
CSF WBC (× 106/L) 25 (9.5, 92)b 179 (26, 271)b, c 212 (91, 1434)b, c 1.0 (1.0, 2.0) < 0.001
CSF protein (g/L) 0.57 (0.4, 0.9)b 0.59 (0.4, 0.8)b 2.2 (0.8, 5.9)b, c, d 0.26 (0.2, 0.3) < 0.001
CSF glucose (mmol/L) 3.6 (3.3, 4.4) 3.5 (3.0, 3.7) 3.6 (0.4, 6.3) 3.5 (3.2, 3.7) 0.341
Glucose ratio 0.6 (0.5, 0.7) 0.6 (0.5, 0.6)b 0.4 (0.1, 0.6)b 0.6 (0.6, 0.7) 0.009
Albumin ratio 8.4 (6.5,14)b 9.4 (6.1, 13)b 79 (36, 137)b, c, d 4.0 (2.6, 5.0) < 0.001
Blood WBC (× 109/L) 8.6 (7.4, 11) 8.2 (6.1, 11) 14 (8.5, 18) 10 (6.7, 12) 0.173
CRP, serum (mg/L) 6 (0.9, 86) 3.5 (1.3, 12)b 169 (96, 446)b, c, d 16 (2.1, 77) 0.001
CSF WBC white blood cell count in CSF, glucose ratio CSF glucose/serum glucose, albumin ratio CSF albumin/serum albumin. Significant p-values are marked
in bold.
Data shown are median (IQR) or numbers/n (%)
ap values for one way analysis of variance (Kruskal-Wallis)
bp < 0.05 for analysis with Mann-Whitney U test (MWU) in comparison with the control group
cp < 0.05 for analysis with MWU in comparison with encephalitis
dp < 0.05 for analysis with MWU in comparison with ASM
eUnder treatment for or treated for cancer within the last year (including hematological malignancies), HIV infection or diabetes mellitus type 2 (DM2), or using
immunosuppressive or immune modulating drugs
fCausing agents for encephalitis were 3 viral (adenovirus, HSV1, VZV) and 1 NMDAr encephalitis. ABM; Streptococcus pneumonia (n = 2), Staphylococcus aureus (n =
2), Neisseria meningitides (n = 1), and Haemophilus influenzae (n = 1). ASM; HSV2 (n = 6), enterovirus (n = 8), Toscana virus (n = 1), and 1 patient had intrathecal
antibody production of IgG against Borrelia burgdorferi
gNeck stiffness was assessed by a physician before LP
hFever was defined as either ≥ 38 °C upon admission or within 24 h after admission, or measured to ≥ 38 °C by the patient prior to admission
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these patients, the causative bacteria was also de-
tected in blood culture. Patients with encephalitis pre-
sented with less headache and more focal neurology
compared to the other groups, and impairment of
consciousness was observed in significantly fewer
patients with ASM and in the control group. Import-
antly, the majority of the control group had fever,
headache, and neck stiffness, similar to most of the
patients with CNS infection.
Cytokine profiles in CSF and serum
Cytokines analyzed in parallel in CSF and serum
showed distinct patterns for the different patient
groups. Overall, the highest levels of CSF cytokines
were found in patients with ABM, including the
prototypical inflammatory cytokines TNF, IL-1β and
IL-6, inflammatory chemokines (e.g., IL-8, MCP-1,
MIP-1α and MIP-1β), cytokines with potent effect on
T cell function (e.g., IP-10, IL-7, IL-9 and IL-15), and
growth factors (e.g., VEGF and G-CSF) (Fig. 2,
Additional file 3: Table S2). The typical cytokine pat-
tern in CSF was an increase from disease controls
without CNS infection to patients with encephalitis
and ASM with the highest levels in those with ABM.
In contrast to this pattern, the CXC chemokine IP-10
showed the highest median level in the ASM group
(Fig. 2). Although lower than in patients with ABM
and ASM, patients with encephalitis had higher levels
for most cytokines in CSF compared to the control
group, with no significant difference in the levels
between encephalitis cases with or without known eti-
ology (data not shown).
The encephalitis group and the control group gener-
ally showed lower cytokine levels in CSF than in serum,
with exceptions for IL-6 and IL-8 in the encephalitis
group and MCP-1 and IP-10 for both groups (Figs. 2
and 3, Additional file 3: Table S2). In contrast, the
groups with meningeal involvement and in particular the
ABM group displayed markedly higher CSF levels than
serum levels for most cytokines. For some of the cyto-
kines, the CSF levels were more than tenfold higher than
in serum (e.g., IL-6, IL-8, IP-10). In general, serum levels
did not display the striking and significant differences
between the patient groups and controls as seen in CSF
(Fig. 3). In fact, although all patients in the ABM group
had a positive blood culture, only TNF, IL-6, IL-8,
IL-1Ra, and MIP-1α demonstrated higher serum levels
than in the control group.
When we analyzed the CNS infections all together
(encephalitis, ASM, and ABM), a significant correl-
ation between serum and CSF levels were found only
for TNF (Rho 0.4, p = 0.03), IL-1Ra (Rho 0.4, p =
0.03), IL-6 (Rho 0.5, p = 0.004), and MCP-1 (Rho 0.3,
p = 0.04) suggesting intrathecal production of most of
the examined mediators (Additional file 4: Table S3).
Finally, except for MCP-1, all cytokines in CSF corre-
lated positively with the CSF leukocyte counts, and
all, except for MCP-1 and IP-10, correlated with CSF/
serum albumin ratio. Collectively, these data under-
score the limited information obtained from a serum
sample in contrast to that obtained from CSF when
examining the inflammatory network in infectious
CNS diseases.
Profile of tryptophan metabolites and IDO activity in CNS
infections
In order to relate the cytokine profile to tryptophan
metabolism (Fig. 1), metabolites of the KP in the CSF
were examined in patients with encephalitis (n = 10),
those in the ASM group with verified viral cause (VM, n
= 12), ABM (n = 6), and controls (n = 22). The median
levels of most KP metabolites were higher in patients
with encephalitis, VM, and ABM compared with the
controls, with the highest median levels observed in the
ABM group (Fig. 4, Additional file 5: Table S4). The only
exception was TRP, which was lowest in the VM group
(Fig. 4).
The KYN/TRP ratio was higher in all CNS infections
compared to the controls (p = 0.009), indicating an in-
creased conversion of TRP (Fig. 4). Moreover, to evalu-
ate the relationship between putatively neuroprotective
(KYNA) and neurotoxic (3-HK and QA) KP metabolites,
we calculated the KYNA/(3-HK +QA) ratio showing de-
creased levels for patients with encephalitis indicating a
net neurotoxic effect of TRP metabolites in these pa-
tients (Fig. 4).
Most KP metabolites were present at higher concentra-
tions in serum (Additional file 5: Table S4, Additional file 6:
Figure S2) than in CSF (Fig. 2), but with less significant
differences between the groups. For the total group with
CNS infection (encephalitis, VM and ABM), CSF levels
correlated with serum levels for 3-HK (Rho 0.6, p < 0.001),
QA (0.4, p = 0.04), and PIC (0.7, p < 0.001), for all other
KP metabolites, there was no significant correlation be-
tween CSF and serum levels. Furthermore, all CSF/serum
ratios for KP metabolites, except for TRP, KYNA, and PIC
ratio, were positively correlated with CSF WBC count,
while only the ratio of PIC was correlated with CSF albu-
min/serum ratio (Additional file 7: Table S5).
Markers of IFN-γ activation correlate with activation of
the KP
IFN-γ is known to have a major influence on the KP
[37, 38]. In the present study, IFN-γ levels in CSF
were below detection level in 58% of the cases. How-
ever, neopterin, being a reliable and stable marker of
IFN-γ activity [39], was markedly elevated in CSF in
all groups of patients with neuroinflammation
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Fig. 2 (See legend on next page.)
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compared with controls (Fig. 4). Notably, when all
CNS infections were analyzed together, CSF level of
neopterin was strongly positively correlated with IDO
(measured as the KYN/TRP ratio) and inversely cor-
related with the KYNA/(3-HK + QA) ratio (Fig. 5).
This suggests an association between high IFN-γ
activity and net neurotoxic effects of KP metabolites.
A positive correlation was also seen between IDO
and IP-10, another IFN- related cytokine, but no
significant correlation was found between IP-10 and
KYNA/(3-HK + QA) ratio (Fig. 5).
Association of cytokines and metabolites in the KP and
clinical variables
Abnormal regulation of the KP metabolites has been re-
lated to depression [40, 41]. However, excluding the two
patients in the encephalitis group who reported existing
or recent depression from the correlation analyses did
not influence the findings (data not shown). Although
the Glasgow Coma Scale (GCS) is a crude tool, it reflects
the severity of critically ill patients. Among patients with
aseptic meningitis, all but two had a GCS at 15; thus,
only patients with encephalitis and bacterial meningitis
were included in correlation analyses with GCS. We did
not find any significant correlations between cytokine
levels or KP metabolites in CSF and GCS in these
patients (data not shown). However, the number of pa-
tients was too low to make any firm conclusion.
Discussion
In the present study, we demonstrate a gradual increase in
levels of a wide range of cytokines, including chemokines,
interleukins, interferons, and growth factors from enceph-
alitis to ASM and finally to ABM as compared with con-
trols, reflecting the level of CSF inflammation seen in
patients with these CNS infections. Moreover, in ASM
and ABM, the levels were much higher in CSF than in
serum for most of the mediators, even though the patients
with ABM had positive blood cultures for the actual
pathogen. Notably, in contrast to most of the mediators,
IP-10 levels in CSF had the highest median value in the
ASM group, indicating a potential role for this chemokine
in aseptic meningitis. Finally, these changes in inflamma-
tory mediators were associated with marked changes in
KP metabolites in CSF. In particular, all groups of CNS in-
fections had increased IDO activity assessed by KYN/TRP
ratio compared with controls, indicating an increased
catabolism of TRP. Interestingly, patients with encephalitis
and viral meningitis had an unfavorable balance between
neuroprotective and neurotoxic TRP metabolites. These
changes in KP metabolites were associated with CSF levels
of neopterin, and for the KYN/TRP ratio also with IP-10,
suggesting a link between IFN-γ and altered KP metabo-
lites in these patients.
The influx of inflammatory cells and the resulting
dysregulation of cytokine networks may be detrimen-
tal during CNS infection and is thought to contribute
to neurological complications [12, 42–44]. CNS
inflammation is a complex process, depending on
anatomical site (parenchyma vs meninges), cell type
being involved (e.g., infiltrating leukocytes in acute in-
fection vs brain-derived cells), and causing agent (e.g.,
viral vs bacterial). In this study, we describe findings
from patients with acute inflammation in the CNS,
mainly of infectious cause. The levels of cytokines in
CSF were generally higher for all infectious groups
compared to control, and strongly correlated with
each other, demonstrating a general inflammatory re-
sponse in patients with acute CNS infections. The
pattern of increasing levels of inflammatory markers
from encephalitis to aseptic meningitis and finally to
bacterial meningitis indicates increased inflammation
in all subgroup of patients, but with a more modest
CSF inflammation in patients with encephalitis. Not
surprisingly, the highest levels of most of the media-
tors were found in patients with bacterial meningitis
and there was a CSF/serum ratio > 1 of most media-
tors in patients with ABM, despite bacteremia. Fur-
thermore, most cytokines were correlated with CSF
WBC count, but not with corresponding serum levels,
which implies the inflammatory response in the CNS
to be independent of a peripheral immune response
with no or minimal influx or efflux between the two
compartments. These results indicate a predominately
intrathecal production of these mediators in CNS in-
fections. IL-6, IL-8, and TNF in CSF have in several
studies been found to be elevated in meningitis and
have even been proposed as biomarkers in CSF for
bacterial meningitis [6, 45]. We found a general in-
crease for most of the inflammatory mediators in
both ASM and ABM, and our study does not support
the use of one particular cytokine as a diagnostic
marker to distinguish ABM from other CNS condi-
tions, including ASM.
(See figure on previous page.)
Fig. 2 Cytokines in CSF in patients with encephalitis (Enc, n= 10), aseptic meningitis (ASM, n= 25), bacterial meningitis (ABM, n= 6) in comparison with
controls (Ctr, n= 42). Data shown are medians with IQR and all were significant by the Kruskal-Wallis test. Comparisons of two groups were analyzed by
using Mann-Whitney U test. Asterisks above patient groups indicate significant difference vs controls, asterisks above horizontal lines indicate significant
differences between individual groups (Mann-Whitney U test): *p< 0.05, **p< 0.01, and ***p< 0.001. Values below the detection limit were set to the
lowest detectable level for that analyte
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Fig. 3 (See legend on next page.)
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In contrast to most of the inflammatory markers,
IP-10 levels were comparable in patients with ASM and
ABM. IP-10 is secreted by several cell types in response
to IFN-γ, and experimental studies have shown that
IP-10 is highly induced in the CNS (e.g., West Nile in-
fections [46], HIV encephalitis [47], HSV encephalitis
[48], enteroviral encephalitis [3, 49], Japanese encephal-
itis [50], and tick-borne encephalitis [TBE] [51]). In-
creased levels have also been reported in patients
suffering from TBE [52], neuroborreliosis [53], entero-
virus infection [3], HSV meningitis, and HSV encephal-
itis [9]. IP-10 is a chemoattractant for monocytes and
macrophages and promotes T cell recruitment, especially
of CD8+ T cells [46, 54, 55]. Although IP-10 has been
linked to viral clearance in the CNS [48, 55], IP-10 has
also been described to promote apoptosis of neurons
and excessive production has been associated with more
severe outcome [47, 50, 51]. In the present study, we
found an association between IP-10 and the KYN/TRP
ratio, indicating increased IDO activity and catabolism
of TRP with potential harmful effects on CNS. Thus,
our present data may further support a potential role for
this chemokine in CNS infections, particularly in ASM.
This should be further investigated.
Neurologic dysfunction is common in patients with
encephalitis and bacterial meningitis, and dysregulation
of the KP has been shown in syndromes and disorders
with certain overlap in symptoms [21, 30, 32, 56, 57].
Herein, we compared these metabolites in patients with
a stringent definition of etiology; encephalitis, confirmed
viral meningitis, and bacterial meningitis. Recent litera-
ture has shown that in HSV encephalitis, a low level of
the neuroprotective metabolite KYNA was associated
with more severe outcome [31]. In TB meningitis, low
TRP was associated with a better survival rate [34]. In
our study, the ratio of the neuroprotective metabolite
KYNA to the sum of neurotoxic metabolites 3-HK and
QA was lower for patients with encephalitis compared
to the other groups, which could indicate a stronger ac-
tivation of the KMO branch in encephalitis. In fact,
studies are ongoing regarding the inhibition of several
steps in the KP, including studies on centrally available
KMO inhibitors [58].
In the present study, we observed very low levels of
TRP for several patients with CNS infection, especially
in patients with ASM. We hypothesize that this results
from increased IDO activity, as these patients had a sig-
nificantly higher level of KYN compared to patients with
detectable TRP levels. The strong correlation of KYN/
TRP ratio with neopterin and IP-10 indicates that this
IDO activity is driven by IFN-γ. IDO has been found to
exhibit an immunosuppressive effect by upregulation of
Tregs and downregulation of Th17 cells, which could be
relevant in CNS infections, especially in ASM where T
cells are of particular importance. In contrast to the as-
sociation with IDO activity, neopterin, but not IP-10,
was associated with a “neurotoxic” KYNA/(3-HK +QA)
ratio in patients with CNS infection. The lack of correl-
ation of IP-10 to KYNA/(3-HK +QA) could be related
to low statistical power. However, whereas IP-10 is in-
duced by IFN- γ in several cell types including mono-
cytes, stromal cells, and endothelial cells [59], neopterin
is almost selectively produced in monocytes/macro-
phages, and through its relation to tetrahydrobiopterin,
neopterin may be more closely related to tryptophan
metabolism than IP-10 [60, 61].
Finally, when looking at the CSF/serum ratios of KP
metabolites, we found very narrow ranges in the control
group, suggesting strict control of KP in healthy
subjects.
Studies of the inflammatory profile in human CNS
infections including both meningeal and parenchymal
infections are relatively scarce [62–65], and comparisons
between different studies are hampered by the diversity
of causing agents and divergent inclusion criteria. Never-
theless, knowledge of immunological mechanism is piv-
otal in order to develop better diagnostic and potentially
therapeutic tools for these patients. To our knowledge,
the measurement of a large panel of metabolites in the
KP in both serum and CSF, with parallel analyses of a
wide range of cytokines and related mediators, have not
been reported for patients with these conditions, espe-
cially not for encephalitis. Moreover, the correlation in
present study of IP-10 and neopterin with the KP metab-
olites and the decreased KYNA/(3-HK +QA) ratio in
encephalitis are interesting findings that, as far as we are
aware of, have not been reported in these clinical rele-
vant CNS infections. However, the present study also
has some limitations. The subgroups of patients, and in
particular patients with ABM and encephalitis, were
small and too small for sub-analyses on causing agents.
Moreover, the etiology was unknown for 60% of patients
with encephalitis with few patients with confirmed viral
cause. Besides, due to lack of reliable measures of sever-
ity and outcome, together with the relatively low number
of patients with CNS infection, we cannot make any
(See figure on previous page.)
Fig. 3 Cytokines in serum in patients with encephalitis (Enc, n= 10), aseptic meningitis (ASM, n= 20), bacterial meningitis (ABM, n= 6) in comparison with
controls (Ctr, n= 41). Data shown are medians with IQR. Asterisks above patient groups indicate significant difference vs controls, asterisks above horizontal
lines indicate significant differences between individual groups (Mann-Whitney U test): *p< 0.05, **p< 0.01, and ***p< 0.001. Values below the detection
limit were set to the lowest detectable level for that analyte
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conclusion regarding the use of these cytokines and me-
tabolites as prognostic markers. The control group in
our study consisted of patients with similar presentation
and no pleocytosis, but many of these patients suffered
from systemic infections, as reflected by elevated serum
neopterin levels. This may have camouflaged significant
Fig. 4 Neopterin, kynurenine metabolites, and ratios in patients with encephalitis (Enc, n = 10), viral meningitis (VM, n = 12), and bacterial
meningitis (ABM, n = 6) in comparison with controls (Ctr, n = 22). Data shown are median with IQR, and all were significant in the analysis of
variance with the Kruskal-Wallis test. Comparisons of two groups were analyzed by Mann-Whitney U test. Asterisks above patient groups indicate
significant difference vs controls, asterisks above horizontal lines indicate significant differences between individual groups (Mann-Whitney U test):
*p < 0.05, **p < 0.01, and ***p < 0.001. a: TRP levels below the lower level of detection (LOD) for 9 patients with CNS infection were adjusted to
this value (0.4 μM) for calculation of the KYN/TRP ratio as the expression of IDO activity (KYN (nmol)/TRP(μmol))
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findings in serum profiles. On the other hand, these
controls may be more clinically relevant than healthy
controls without any disease symptoms like fever and
headache. Finally, correlations do not necessarily
mean any causal relationship and more mechanistic
studies as well as larger studies with samples also
taken during follow-up are needed to make firmer
conclusions.
Conclusions
In conclusion, we found a marked increase in a wide range
of inflammatory mediators in CSF in aseptic and bacterial
meningitis with a more modest increase in encephalitis.
The markedly higher levels in CNS than in serum for
most of the mediators indicate compartmentalization of
immune responses in the CSF. Our data may also suggest
that increased IFN-γ activity, as assessed by neopterin and
IP-10, may contribute to neurotoxicity through enhanced
TRP catabolism. In particular, dysregulation of the KP
with signs of an increased formation of neurotoxic QA in
encephalitis should be explored further in these
conditions.
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